Flavokawain A

Name: Flavokawain A
Brand: MedChemExpress
SKU: HY-N2420
Rating: 5.0 (2 reviews)

Cat. No.: HY-N2420 Purity: 99.73%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer.

For research use only. We do not sell to patients.

CAS No. : 3420-72-2

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Flavokawain A:

(E)-Flavokawain A In-stock
Flavokawain A (Standard) Get quote

2 Publications Citing Use of MCE Flavokawain A

Others

Cell Proliferation/Viability Assay

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) decreases the viability in AML cell lines. MV4-11, MOLM-13, THP-1, and U937 cells were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 24 and 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605; 7.3 μg/mL) was used as a positive control.

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) induces cell cycle arrest in AML cells. MV4–11 cells were treated with or without FKA (5 and 10 μg/mL) for 48 h an cell cycle was examined by flow cytometry.

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) regulates p27 through CDT1 in AML cells. MV4–11 cells with or without CDT1 overexpression were treated with FKA (10 μg/mL), the expression of CDT1 and p27 were shown.

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) targets primary AML blasts. Samples from AML patients were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605) was used as a positive control. Data were shown as mean ± SD from at least three independent experiments.

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]; SUDHL-4 and OCI-Ly3 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

: Flavokawain A purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2023 Nov:120:155074. [Abstract]; Raji and Jeko-1 cells were treated with FKA (Flavokawain A; HY-N2420; 1.25-20 µg/mL) or Doxorubicin (HY-15142A; 10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.SUDHL-4 (A), OCI-Ly3 (B), Raji (C), and Jeko-1 (D) cells were treated with FKA (1.25-20 µg/mL) or doxorubicin (10 µM) for 24 and 48 h. Cell viability was measured using the MTS assay. *P < 0.05, #P < 0.01, †P < 0.001, and ‡P < 0.0001 versus control at corresponding time points.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Methyltransferase Isoform Specific Products:

View All Isoforms

EZH1 EZH2 DOT1L SMYD2 SMYD3 SUV39H2/KMT1B EHMT2/G9a/KMT1C EHMT1/GLP/KMT1D ASH1L/KMT2H SETDB1/KMT2G SETD2/KMT3A NSD2/MMSET/WHSC1 NSD3/WHSC1L1 SETD7/KMT7 SETD8/KMT5A PRMT1 PRMT3 PRMT4 PRMT5 PRMT6 PRMT7 PRMT8

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All IAP Isoform Specific Products:

View All Isoforms

cIAP cIAP-1 cIAP-2 XIAP

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All NO Synthase Isoform Specific Products:

View All Isoforms

nNOS iNOS eNOS

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

View All JNK Isoform Specific Products:

View All Isoforms

JNK1 JNK2 JNK3 JNK

View All ERK Isoform Specific Products:

View All Isoforms

ERK ERK1 ERK2 ERK5 ERK8

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.6 μg/mL Compound: Flavokawain A	Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB expressed in human A549 cells treated 1 hr after TNFalpha challenge measured after 6 hrs by luciferase reporter gene assay	[PMID: 19716299]
A549	IC₅₀	> 20 μM Compound: 6	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
DU-145	GI₅₀	30.8 μM Compound: 4	Cytotoxicity against human DU145 cells after 48 hrs Cytotoxicity against human DU145 cells after 48 hrs	[PMID: 18798609]
HCT-116	IC₅₀	10.6 μM Compound: 1c	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 30041135]
HT-29	GI₅₀	45.3 μM Compound: 4	Cytotoxicity against human HT29 cells after 48 hrs Cytotoxicity against human HT29 cells after 48 hrs	[PMID: 18798609]
K562	GI₅₀	20.5 μM Compound: 4	Cytotoxicity against human K562 cells after 48 hrs Cytotoxicity against human K562 cells after 48 hrs	[PMID: 18798609]
M14	GI₅₀	22.5 μM Compound: 4	Cytotoxicity against human M14 cells after 48 hrs Cytotoxicity against human M14 cells after 48 hrs	[PMID: 18798609]
MCF7	GI₅₀	17.5 μM Compound: 4	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 18798609]
MDCK-II	IC₅₀	3 μM Compound: 24	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by fluorimetry Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation preincubated for 30 mins by fluorimetry	[PMID: 22112540]
NCI-H460	GI₅₀	24.1 μM Compound: 4	Cytotoxicity against human H460 cells after 48 hrs Cytotoxicity against human H460 cells after 48 hrs	[PMID: 18798609]
NIH3T3	GI₅₀	17.2 μM Compound: 4	Cytotoxicity against BALB mouse 3T3 cells after 48 hrs Cytotoxicity against BALB mouse 3T3 cells after 48 hrs	[PMID: 18798609]
NIH3T3	IC₅₀	11 μM Compound: 2a	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PC-3	GI₅₀	15.2 μM Compound: 4	Cytotoxicity against human PC3 cells after 48 hrs Cytotoxicity against human PC3 cells after 48 hrs	[PMID: 18798609]
Vero	IC₅₀	> 25 μM Compound: 4	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 in african green monkey Vero cells after 120 hrs Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 in african green monkey Vero cells after 120 hrs	[PMID: 18798609]

In Vitro

Flavokawain A (0.05-25 μg/mL; 4-48 h) can inhibit the proliferation of multiple bladder cancer cells, cause the loss of mitochondrial membrane potential and the release of cytochrome c in T24 cells. The mechanism involves the activation of Bax and the inhibition of Bcl-x/L^[1].
Flavokawain A (5-30 μg/mL; 4-24 h) induces apoptosis in T24 cells through the caspase pathway and by inhibiting XIAP and survivin^[1].
Flavokawain A (20-40 μM; 24 h) can inhibit IL-1β-induced inflammation, the expression of senescence-related genes, apoptosis, and the phosphorylation of genes related to the MAPK and PI3K pathways in mouse chondrocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	RT4, T24, and EJ cells
Concentration:	RT4 cells (0.05, 0.5, 5, 12.5 and 25 μg/mL) T24 and EJ cells (0.309, 0.625, 1.25, 2.5, 5, 12.5 and 25 μg/mL)
Incubation Time:	48 h
Result:	Inhibited cell proliferation in RT4, T24, and EJ bladder cancer cell lines

Western Blot Analysis^[1]

Cell Line:	T24 cells
Concentration:	12.5 μg/mL
Incubation Time:	4, 8, 16 and 24 h
Result:	Inhibited the level Bcl-x/L. Increased the level Bax.

Western Blot Analysis^[1]

Cell Line:	T24 cells
Concentration:	5, 10, 20 and 30μg/mL
Incubation Time:	4, 8, 16 and 24 h
Result:	Inhibited the levels of XIAP and survivin.

Western Blot Analysis^[2]

Cell Line:	IL-1β treated mouse chondrocyte cells
Concentration:	20 and 40 μM
Incubation Time:	24 h
Result:	Inhibited the levels of iNOS and COX2. Inhibited the levels of P16 and P21. Inhibited the level of Bax and increased the level of Bcl2. Inhibited the phosphorylation levels of JNK, P38, ERK, PI3K, AKT and mTOR.

In Vivo

Flavokawain A (30 mg/kg; peritumoral injection; once every 3 days; 24 days) exhibits anti-tumor activity in a mouse model of bladder cancer^[3].
Flavokawain A (50 mg/kg; oral administration; 28 days) shows no toxicity and has certain immunomodulatory effects in Balb/c mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male BALB/c mice aged 8 weeks old^[4]
Dosage:	50 mg/kg/day
Administration:	Oral administration (p.o.); 28 days
Result:	Did not cause the death of mice during the 28-day treatment period, and there were no significant changes in the body weight of the mice. Did not significantly alter several serum biochemical parameters. Stimulated the proliferation of splenocytes, promoted the secretion of cytokines IL-2 and TNF-α, and increased the population of T cell subsets. Decreased the levels of TNF-α and NO, and slightly reduced the level of IL-2.

Animal Model:	Four-week-old Balb/c nude mice treated UMUC3 cells^[3]
Dosage:	30 mg/kg
Administration:	Peritumoral injection; once every 3 days; 24 days
Result:	Significantly inhibited tumor size. Decreased the arginine methylation level of histone and the expression of bladder-cancer-associated regulon genes.

Molecular Weight

314.33

Formula

C₁₈H₁₈O₅

CAS No.

3420-72-2

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=C(OC)C=C(OC)C=C1O)/C=C/C2=CC=C(OC)C=C2

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (318.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1814 mL	15.9069 mL	31.8137 mL
5 mM	0.6363 mL	3.1814 mL	6.3627 mL
10 mM	0.3181 mL	1.5907 mL	3.1814 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (279 KB) SDS (396 KB)

COA (246 KB) HNMR (238 KB) LCMS (344 KB)

Handling Instructions (2659 KB)

References

[1]. Xiaolin Zi, et al. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 2005 Apr 15;65(8):3479-86. [Content Brief]

[2]. Jing S, et al. Flavokawain A alleviates the progression of mouse osteoarthritis: An in vitro and in vivo study. Front Bioeng Biotechnol. 2022 Dec 5;10:1071776. [Content Brief]

[3]. Liu S, et al. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer. J Exp Clin Cancer Res. 2022 Oct 5;41(1):293. [Content Brief]

[4]. Abu N, et al. In vitro Toxicity and in vivo Immunomodulatory Effects of Flavokawain A and Flavokawain B in Balb/C Mice. Nat Prod Commun. 2015 Jul;10(7):1199-202. [Content Brief]

[5]. Niu L, et al. Flavokawain A inhibits Cytochrome P450 in in vitro metabolic and inhibitory investigations. J Ethnopharmacol. 2016 Sep 15;191:350-359. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1814 mL	15.9069 mL	31.8137 mL	79.5343 mL
	5 mM	0.6363 mL	3.1814 mL	6.3627 mL	15.9069 mL
	10 mM	0.3181 mL	1.5907 mL	3.1814 mL	7.9534 mL
	15 mM	0.2121 mL	1.0605 mL	2.1209 mL	5.3023 mL
	20 mM	0.1591 mL	0.7953 mL	1.5907 mL	3.9767 mL
	25 mM	0.1273 mL	0.6363 mL	1.2725 mL	3.1814 mL
	30 mM	0.1060 mL	0.5302 mL	1.0605 mL	2.6511 mL
	40 mM	0.0795 mL	0.3977 mL	0.7953 mL	1.9884 mL
	50 mM	0.0636 mL	0.3181 mL	0.6363 mL	1.5907 mL
	60 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3256 mL
	80 mM	0.0398 mL	0.1988 mL	0.3977 mL	0.9942 mL
	100 mM	0.0318 mL	0.1591 mL	0.3181 mL	0.7953 mL

Flavokawain A Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Flavokawain A

Customer Review

Other Forms of Flavokawain A:

2 Publications Citing Use of MCE Flavokawain A

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Methyltransferase Isoform Specific Products:

View All Cytochrome P450 Isoform Specific Products:

View All Caspase Isoform Specific Products:

View All IAP Isoform Specific Products:

View All p38 MAPK Isoform Specific Products:

View All PI3K Isoform Specific Products:

View All NO Synthase Isoform Specific Products:

View All COX Isoform Specific Products:

View All JNK Isoform Specific Products:

View All ERK Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Flavokawain A Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Flavokawain A

Customer Review

Other Forms of Flavokawain A:

Flavokawain A Related Antibodies

2 Publications Citing Use of MCE Flavokawain A

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Histone Methyltransferase Isoform Specific Products:

View All Cytochrome P450 Isoform Specific Products:

View All Caspase Isoform Specific Products:

View All IAP Isoform Specific Products:

View All p38 MAPK Isoform Specific Products:

View All PI3K Isoform Specific Products:

View All NO Synthase Isoform Specific Products:

View All COX Isoform Specific Products:

View All JNK Isoform Specific Products:

View All ERK Isoform Specific Products:

View All Akt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Flavokawain A Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Flavokawain A Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report